Remote ischemic preconditioning prevents sarcolemmal-associated proteolysis by MMP-2 inhibition.

Cardioprotection Ischemia Myocardial infarction Remote preconditioning Reperfusion

Journal

Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456

Informations de publication

Date de publication:
20 Sep 2023
Historique:
received: 01 12 2022
accepted: 02 09 2023
medline: 20 9 2023
pubmed: 20 9 2023
entrez: 20 9 2023
Statut: aheadofprint

Résumé

The death of myocytes occurs through different pathways, but the rupture of the plasma membrane is the key point in the transition from reversible to irreversible injury. In the myocytes, three major groups of structural proteins that link the extracellular and intracellular milieus and confer structural stability to the cell membrane: the dystrophin-associated protein complex, the vinculin-integrin link, and the spectrin-based submembranous cytoskeleton. The objective was to determine if remote ischemic preconditioning (rIPC) preserves membrane-associated cytoskeletal proteins (dystrophin and β-dystroglycan) through the inhibition of metalloproteinase type 2 (MMP-2) activity. A second objective was to describe some of the intracellular signals of the rIPC, that modify mitochondrial function at the early reperfusion. Isolated rat hearts were subjected to 30 min of global ischemia and 120 min of reperfusion (I/R). rIPC was performed by 3 cycles of ischemia/reperfusion in the lower limb (rIPC). rIPC significantly decreased the infarct size, induced Akt/GSK-3 β phosphorylation and inhibition of the MPTP opening. rIPC improved mitochondrial function, increasing membrane potential, ATP production and respiratory control. I/R increased ONOO

Identifiants

pubmed: 37728809
doi: 10.1007/s11010-023-04849-2
pii: 10.1007/s11010-023-04849-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Agency for Scientific and Technological Promotion
ID : ANPCyT, PICT 2017-1447
Organisme : Universidad de Buenos Aires
ID : UBACyT 20020150100105BA

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Bell RM, Basalay M, Bøtker HE, Beikoghli Kalkhoran S, Carr RD, Cunningham J, Davidson SM, England TJ, Giesz S, Ghosh AK, Golforoush P, Gourine AV, Hausenloy DJ, Heusch G, Ibanez B, Kleinbongard P, Lecour S, Lukhna K, Ntsekhe M, Ovize M, Salama AD, Vilahur G, Walker JM, Yellon DM (2022) Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop. Basic Res Cardiol 117(1):39. https://doi.org/10.1007/s00395-022-00947-2
doi: 10.1007/s00395-022-00947-2 pubmed: 35970954 pmcid: 9377667
Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Böning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schön J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K, RIPHeart Study Collaborators (2015) A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med. 373(15):1397–407. https://doi.org/10.1056/NEJMoa1413579
doi: 10.1056/NEJMoa1413579 pubmed: 26436208
Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM (2015) Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373(15):1408–17. https://doi.org/10.1056/NEJMoa1413534)
doi: 10.1056/NEJMoa1413534) pubmed: 26436207
Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister AF (2002) Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 106:2881–2883. https://doi.org/10.1161/01.cir.0000043806.51912.9b
doi: 10.1161/01.cir.0000043806.51912.9b pubmed: 12460865
Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM (2007) Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet 370:575–579. https://doi.org/10.1016/S0140-6736(07)61296-3
doi: 10.1016/S0140-6736(07)61296-3 pubmed: 17707752
Candilio L, Malik A, Ariti C, Barnard M, Di SC, Lawrence D, Hayward M, Yap J, Roberts N, Sheikh A, Kolvekar S, Hausenloy DJ, Yellon DM (2015) Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. Heart 10:185–192. https://doi.org/10.1136/heartjnl-2014-306178
doi: 10.1136/heartjnl-2014-306178
Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-Centre randomised, double-blind, controlled trial. Lancet 382:597–604. https://doi.org/10.1016/S0140-6736(13)61450-6
doi: 10.1016/S0140-6736(13)61450-6 pubmed: 23953384
Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K, Collaborators RIS (2015) A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373:1397–1407. https://doi.org/10.1056/NEJMoa1413579
doi: 10.1056/NEJMoa1413579 pubmed: 26436208
Rodríguez M, Cai WJ, Kostin S, Lucchesi BR, Schaper J (2005) Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 38(5):723–733. https://doi.org/10.1016/j.yjmcc.2005.02.019
doi: 10.1016/j.yjmcc.2005.02.019 pubmed: 15850566
Buchholz B, Perez V, Siachoque N, Miksztowicz V, Berg G, Rodríguez M, Donato M, Gelpi RJ (2014) Dystrophin proteolysis: a potential target for MMP-2 and its prevention by ischemic preconditioning. Am J Physiol Heart Circ Physiol 307(1):H88-96. https://doi.org/10.1152/ajpheart.00242.2013
doi: 10.1152/ajpheart.00242.2013 pubmed: 24791785
Schwarz ER, Somoano Y, Hale SL, Kloner RA (2000) Share. What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat? J Thromb Thrombolysis 10(2):181–7. https://doi.org/10.1023/a:1018770711705
doi: 10.1023/a:1018770711705 pubmed: 11005940
Ale-Agha N, Jakobs P, Goy C, Zurek M, Rosen J, Dyballa-Rukes N et al (2021) Mitochondrial telomerase reverse transcriptase protects from myocardial ischemia/reperfusion injury by improving complex I composition and function. Circulation 144(23):1876–1890. https://doi.org/10.1161/CIRCULATIONAHA.120.051923
doi: 10.1161/CIRCULATIONAHA.120.051923 pubmed: 34672678
Kleinbongard P, Gedik N, Kirca M, Stoian L, Frey U, Zandi A et al (2018) Mitochondrial and contractile function of human right atrial tissue in response to remote ischemic conditioning. J Am Heart Assoc 7(15):e009540. https://doi.org/10.1161/JAHA.118.009540
doi: 10.1161/JAHA.118.009540 pubmed: 30371229 pmcid: 6201459
Skyschally A, Kleinbongard P, Lieder H, Gedik N, Stoian L, Amanakis G et al (2018) Humoral transfer and intramyocardial signal transduction of protection by remote ischemic perconditioning in pigs, rats, and mice. Am J Physiol Heart Circ Physiol 315(1):H159–H172. https://doi.org/10.1152/ajpheart.00152.2018
doi: 10.1152/ajpheart.00152.2018 pubmed: 29569956
Mastitskaya S, Basalay M, Hosford PS, Ramage AG, Gourine A, Gourine AV (2016) Identifying the Source of a Humoral Factor of Remote (Pre) Conditioning Cardioprotection. PLoS One 11(2):e0150108. https://doi.org/10.1371/journal.pone.0150108
doi: 10.1371/journal.pone.0150108 pubmed: 26918777 pmcid: 4769182
Donato M, Goyeneche MA, Garces M, Marchini T, Pérez V, Del Mauro J, Höcht C, Rodríguez M, Evelson P, Gelpi RJ (2016) Myocardial triggers involved in activation of remote ischaemic preconditioning. Exp Physiol 101(6):708–716. https://doi.org/10.1113/EP085535
doi: 10.1113/EP085535 pubmed: 27028009
Donato M, Buchholz B, Rodríguez M, Pérez V, Inserte J, García-Dorado D, Gelpi RJ (2013) Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. Exp Physiol 98(2):425–34. https://doi.org/10.1113/expphysiol.2012.066217
doi: 10.1113/expphysiol.2012.066217 pubmed: 22872660
Patel HH, Moore J, Hsu AK, Gross GJ (2002) Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol 34(10):1317–1323. https://doi.org/10.1006/jmcc.2002.2072
doi: 10.1006/jmcc.2002.2072 pubmed: 12392992
Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M (2014) Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 114(10):1601–10. https://doi.org/10.1161/CIRCRESAHA.114.303822
doi: 10.1161/CIRCRESAHA.114.303822 pubmed: 24643960
Schoemaker RG, Van Heijningen CL (2000) Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol 278(5):H1571–H1576. https://doi.org/10.1152/ajpheart.2000.278.5.H1571
doi: 10.1152/ajpheart.2000.278.5.H1571 pubmed: 10775135
Gedik N, Maciel L, Schulte C, Skyschally A, Heusch G, Kleinbongard P (2017) Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning. Arch Med Sci. 13(2):448–458. https://doi.org/10.5114/aoms.2016.61789
doi: 10.5114/aoms.2016.61789 pubmed: 28261301
Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM (2016) Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol 111(4):50. https://doi.org/10.1007/s00395-016-0568-z
doi: 10.1007/s00395-016-0568-z pubmed: 27338249 pmcid: 4919370
Wilson DGS, Tinker A, Iskratsch T (2022) The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction. Commun Biol 5(1):1022. https://doi.org/10.1038/s42003-022-03980-y
doi: 10.1038/s42003-022-03980-y pubmed: 36168044 pmcid: 9515174
Kyoi S, Otani H, Hamano A, Matsuhisa S, Akita Y, Fujiwara H, Hattori R, Imamura H, Kamihata H, Iwasaka T (2006) Dystrophin is a possible end-target of ischemic preconditioning against cardiomyocyte oncosis during the early phase of reperfusion. Cardiovasc Res 70(2):354–363. https://doi.org/10.1016/j.cardiores.2006.01.004
doi: 10.1016/j.cardiores.2006.01.004 pubmed: 16466703
Hughes BG, Schulz R (2014) Targeting MMP-2 to treat ischemic heart injury. Basic Res Cardiol 109(4):424. https://doi.org/10.1007/s00395-014-0424-y
doi: 10.1007/s00395-014-0424-y pubmed: 24986221
Dalal S, Shook PL, Singh M, Singh K (2023) Post-ischemic cardioprotective potential of exogenous ubiquitin in myocardial remodeling late after ischemia/reperfusion injury. Life Sci 312:121216. https://doi.org/10.1016/j.lfs.2022.121216
doi: 10.1016/j.lfs.2022.121216 pubmed: 36435225
Bassiouni W, Ali MAM, Schulz R (2021) Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J 288(24):7162–7182. https://doi.org/10.1111/febs.15701
doi: 10.1111/febs.15701 pubmed: 33405316
Kandasamy AD, Chow AK, Ali MA, Schulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85(3):413–423. https://doi.org/10.1093/cvr/cvp268
doi: 10.1093/cvr/cvp268 pubmed: 19656780
Donato M, D’Annunzio V, Buchholz B, Miksztowicz V, Carrión CL, Valdez LB, Zaobornyj T, Schreier L, Wikinski R, Boveris A, Berg G, Gelpi RJ (2010) Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning. Exp Physiol 95(2):274–281. https://doi.org/10.1113/expphysiol.2009.049874
doi: 10.1113/expphysiol.2009.049874 pubmed: 19880538
Horowitz JD, Chong CR (2020) Matrix metalloproteinase-2 activation: critical to myocardial contractile dysfunction following ischaemia-reperfusion. Cardiovasc Res 116(5):876–878. https://doi.org/10.1093/cvr/cvz271
doi: 10.1093/cvr/cvz271 pubmed: 31800010
Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM (2005) Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436(7053):1025–1029. https://doi.org/10.1038/nature03844
doi: 10.1038/nature03844 pubmed: 16025101
Townsend D, Yasuda S, McNally E, Metzger JM (2011) Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J 25(9):3106–3114. https://doi.org/10.1096/fj.10-178913
doi: 10.1096/fj.10-178913 pubmed: 21665956 pmcid: 3157690
Dexter JR, Mikako H, Elizabeth M, Jason K (2022) Mitochondrial permeability transition pore-dependent necrosis. J Mol Cell Cardiol S0022–2828(22):00563–00566. https://doi.org/10.1016/j.yjmcc.2022.11.003
doi: 10.1016/j.yjmcc.2022.11.003
Morciano G, Bonora M, Campo G, Aquila G, Rizzo P, Giorgi C et al (2017) Mechanistic role of mPTP in ischemia-reperfusion injury. Adv Exp Med Biol 982:169–189. https://doi.org/10.1007/978-3-319-55330-6_9
doi: 10.1007/978-3-319-55330-6_9 pubmed: 28551787
Heusch G (2020) Myocardial ischaemia–reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17(12):773–789. https://doi.org/10.1038/s41569-020-0403-y
doi: 10.1038/s41569-020-0403-y pubmed: 32620851
Jensen RV, Stottrup NB, Kristiansen SB, Botker HE (2012) Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol 107:285. https://doi.org/10.1007/s00395-012-0285-1
doi: 10.1007/s00395-012-0285-1 pubmed: 22821347

Auteurs

Eliana P Bin (EP)

Universidad de Buenos Aires, Facultad de Ciencias Médicas, Instituto de Fisiopatología Cardiovascular, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Tamara Zaobornyj (T)

Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Físico-Química, Buenos Aires, Argentina.

Mariana Garces (M)

Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Verónica D'Annunzio (V)

Universidad de Buenos Aires, Facultad de Ciencias Médicas, Instituto de Fisiopatología Cardiovascular, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Bruno Buchholz (B)

Universidad de Buenos Aires, Facultad de Ciencias Médicas, Instituto de Fisiopatología Cardiovascular, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Timoteo Marchini (T)

Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Pablo Evelson (P)

Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Ricardo J Gelpi (RJ)

Universidad de Buenos Aires, Facultad de Ciencias Médicas, Instituto de Fisiopatología Cardiovascular, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina.
Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina.

Martín Donato (M)

Universidad de Buenos Aires, Facultad de Ciencias Médicas, Instituto de Fisiopatología Cardiovascular, 950 J. E. Uriburu, 2nd floor, C1114AAD, Buenos Aires, Argentina. mdonato@fmed.uba.ar.
Universidad de Buenos Aires - CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina. mdonato@fmed.uba.ar.

Classifications MeSH